Clémentine Sarkozy
Hospices Civils de Lyon · Institut Gustave Roussy Cancer Campus Grand Paris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Clémentine Sarkozy as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:55 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03664336 · Refractory Diffuse Large B-cell LymphomaHospices Civils de Lyon · completed · Diffuse Large B-cell Lymphoma · principal investigator
- Ph1/Ph2NCT02889523 · Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyThe Lymphoma Academic Research Organisation · active not recruiting · Lymphoma, DLBCL, Follicular Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:55 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.J Clin Oncol · 2016159 citationsRCR 4.7
- 77 citationsRCR 2.4
- A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.Clin Cancer Res · 202064 citationsRCR 2.5
- Outcome of older patients with acute myeloid leukemia in first relapse.Am J Hematol · 201341 citationsRCR 1.0
- A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.Haematologica · 201936 citationsRCR 1.4
- Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.Br J Haematol · 201432 citationsRCR 0.9
- 15 citationsRCR 3.0
- 11 citationsRCR 0.3
- 11 citationsRCR 1.3
- 10 citationsRCR 0.4